trending Market Intelligence /marketintelligence/en/news-insights/trending/u5qAoYbljefbnvt5IZUk2g2 content esgSubNav
In This List

Australian regulator approves Endologix's abdominal aortic aneurysm treatment

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Australian regulator approves Endologix's abdominal aortic aneurysm treatment

The Australian Therapeutic Goods Administration approved Endologix Inc.'s AFX2 Bifurcated Endograft System for inclusion on the Australian register of therapeutic goods.

The regulator has approved the use of AFX2 for the treatment of abdominal aortic aneurysms.

Endologix CEO John McDermott said the approval in Australia will allow the company to start offering the latest version of the anatomical fixation system to physicians and patients starting in 2017.